Search - tctmd.com

Displaying 21 - 40 of 132

Sort: Relevancy | Date

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

News Daily News

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

October 29, 2019

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

News Daily News

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

Yael L. Maxwell

October 16, 2019

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

News Daily News

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

October 15, 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

October 08, 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

October 03, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

September 29, 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

News Conference News TCT 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Yael L. Maxwell

September 29, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

Presentation TCT 2019

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

Presenter: Pascal Vranckx

September 28, 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Aspirin Variability, Interactions and Impact of Different Formulations

Presentation TCT 2019

Aspirin Variability, Interactions and Impact of Different Formulations

Presenter: Dominick Angiolillo

September 28, 2019

Evidence for Chronic Aspirin Use in CV Patients: COMPASS and More

Presentation TCT 2019

Evidence for Chronic Aspirin Use in CV Patients: COMPASS and More

Presenter: Sanjit Jolly

September 28, 2019

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Presentation TCT 2019

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Presenter: C. Michael Gibson

September 28, 2019

Aspirin Use for Primary and Secondary Prevention: Critical Appraisal of What We Know and What We Don't

Presentation TCT 2019

Aspirin Use for Primary and Secondary Prevention: Critical Appraisal of What We Know and What We Don't

Presenter: Davide Capodanno

September 28, 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

September 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.